Hasegawa T, Ishihara K, Fujii H, Hajiro T, Watanabe I, Nishimura T, Okazaki M, Katakami N, Umeda B
Department of Pulmonary Medicine, Kobe City General Hospital.
Intern Med. 1996 May;35(5):362-6. doi: 10.2169/internalmedicine.35.362.
Although the influence of high dose inhaled steroids on hypothalamo-pituitary-adrenal (HPA) function in patients with asthma has been extensively studied worldwide, there has been limited information on Japanese asthmatics, especially in terms of a prospective analysis of HPA function in the course of time. We analyzed the changes in HPA function using 2 serial short tetracosactrin tests (STT) separated by an interval of one year in 11 Japanese asthmatics who were treated with high dose inhaled steroids alone [beclomethasone dipropionate (BDP); mean dose 982 micrograms/day] during the period between 2 STTs. Mean values of plasma cortisol before administration of ACTH, maximum cortisol and the rise in cortisol in response to ACTH in the 2 STTs were 7.8, 20.5 and 12.7 micrograms/dl for the 1st test, and 8.9, 23.6 and 14.7 micrograms/dl for the 2nd test, respectively. Overall, there was no significant change in the course of time in each of these 3 values. Although the results of the 1st STT proved to be abnormal in 3 patients who had been receiving systemic steroids before their 1st STT, they improved uniformly in their 2nd STT. In the remaining 8 patients, who had never received systemic steroids, 4 patients showed improvements while the other 4 showed deterioration in HPA function in their serial STTs over the course of time. The dose of BDP was 800 micrograms/day in the former 4 patients, while it was 1,200 micrograms/day in the latter 4. Furthermore, only one patient, in whom BDP had been increased from 800 micrograms/day to 1,200 micrograms/day between the 2 tests, developed an abnormal response in the 2nd STT. On the other hand, one patient whose BDP dose was increased from 800 micrograms/day to 1,600 micrograms/day showed an improvement in HPA function in the 2nd test. These results indicate that the threshold dose of BDP which may cause HPA suppression in Japanese asthmatics lies between 800-1,200 micrograms/day, although there is a large inter-individual variation in terms of such doses.
尽管高剂量吸入性类固醇对哮喘患者下丘脑 - 垂体 - 肾上腺(HPA)功能的影响在全球范围内已得到广泛研究,但关于日本哮喘患者的相关信息有限,特别是在对HPA功能随时间变化的前瞻性分析方面。我们对11名日本哮喘患者进行了分析,这些患者在两次连续短程促肾上腺皮质激素试验(STT)期间仅接受高剂量吸入性类固醇[二丙酸倍氯米松(BDP);平均剂量982微克/天]治疗,两次试验间隔一年。在第一次STT中,促肾上腺皮质激素给药前血浆皮质醇的平均值、最大皮质醇以及对促肾上腺皮质激素反应时皮质醇的升高值分别为7.8、20.5和12.7微克/分升;在第二次STT中,相应的值分别为8.9、23.6和14.7微克/分升。总体而言,这三个值在一段时间内均无显著变化。虽然在第一次STT前接受过全身类固醇治疗的3名患者的第一次STT结果被证明异常,但他们在第二次STT中均有改善。在其余8名从未接受过全身类固醇治疗的患者中,4名患者的HPA功能在连续的STT中随时间改善,而另外4名患者则出现恶化。前4名患者的BDP剂量为800微克/天,而后4名患者为1200微克/天。此外,在两次试验之间BDP剂量从800微克/天增加到1200微克/天的仅1名患者在第二次STT中出现异常反应。另一方面,一名BDP剂量从800微克/天增加到1600微克/天的患者在第二次试验中HPA功能得到改善。这些结果表明,在日本哮喘患者中,可能导致HPA抑制的BDP阈值剂量在800 - 1200微克/天之间,尽管在这些剂量方面个体差异较大。